Has Shayla Francis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,477 in general payments to Shayla Francis, MD across 204 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shayla Francis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shayla Francis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shayla Francis, MD

MOHS-Micrographic Surgery · Dallas, TXNPI 1497801005

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,473 and has fallen 71.7% since, to $417 in 2025.

$4,477in general payments, 2019–2025

Across 204 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$999
Regeneron Healthcare Solutions, Inc.$327
Pfizer$324
Lilly USA, LLC$313
Sanofi$310
LEO Pharma Inc.$309
plus $2K from 22 others

What the payments were for

Food & beverage$4,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	48	$999
Regeneron Healthcare Solutions, Inc.	11	$327
Pfizer	13	$324
Lilly USA, LLC	14	$313
Sanofi	13	$310
LEO Pharma Inc.	15	$309
Incyte Corporation	14	$285
Sun Pharmaceutical Industries Inc.	11	$253
Novartis	12	$228
Johnson & Johnson	8	$175
UCB, Inc.	7	$143
Almirall LLC	6	$137
E.r. Squibb & Sons, L.L.C.	4	$102
Journey Medical Corporation	2	$92
Merz North America, Inc.	4	$77
Galderma Laboratories, L.p.	4	$71
Dermira, Inc.	3	$61
Ortho Dermatologics, A Division Of Bausch Health US, LLC	3	$50
DUSA Pharmaceuticals, Inc.	2	$44
Aclaris Therapeutics, Inc.	2	$40
VYNE Pharmaceuticals Inc.	1	$23
Arcutis Biotherapeutics, Inc.	1	$20
Amgen	1	$19
Biofrontera Inc.	1	$17
Dermavant Sciences, Inc.	1	$15
Helsinn Therapeutics (U.S.), Inc.	1	$15
Bristol Myers Squibb	1	$13
Mayne Pharma Commercial LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LITFULO$122

How this compares

$4,477 in reported general payments places this provider in the 70th percentile of 109 mohs-micrographic surgery providers in Texas.

See all mohs-micrographic surgery providers in Texas →

Medicare billing

Part B allowed, 2024

$549,485

Medicare patients

422

Services billed

2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Doxycycline Hyclate	607	$2,855
ValacyclovirValacyclovir Hcl	18	$1,118
Ketoconazole	13	$222
Triamcinolone Acetonide	21	$187
Mupirocin	13	$137

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Dallas

Daniel WitheilerDallas$6K
Trenton CustisDallas$4K
William PostenDallas$3K
Aaron FarbergRockwall$1.5M
Suneel ChilukuriBellaire$288K
Ryan O QuinnSan Antonio$167K
Paul FriedmanHouston$131K
Brent SpencerFrisco$45K
Julie CroleyThe Woodlands$30K
Kayla McNieceBellaire$13K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →